Napsin A is negatively associated with EMT‑mediated EGFR‑TKI resistance in lung cancer cells

Zhou,Linshui; Lv,Xin; Yang,Junchao; Zhu,Yuanhong; Wang,Zhen; Xu,Tingzhen

doi:10.3892/mmr.2018.9075

Napsin A is negatively associated with EMT‑mediated EGFR‑TKI resistance in lung cancer cells

Authors:
- Linshui Zhou
- Xin Lv
- Junchao Yang
- Yuanhong Zhu
- Zhen Wang
- Tingzhen Xu
View Affiliations

Affiliations: Department of Respiratory Medicine, The First Affiliated Hospital of Zhejiang Chinese Medicine University, Hangzhou, Zhejiang 310006, P.R. China
Published online on: May 25, 2018 https://doi.org/10.3892/mmr.2018.9075
Pages: 1247-1252

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‑TKI) have been used as a standard therapy for patients with lung cancer with EGFR‑activating mutations. Epithelial‑mesenchymal transition (EMT) has been reported to be associated with the development of EGFR‑TKI resistance, which limits the clinical efficacy of EGFR‑TKI. Therefore, investigating the resistance‑associated mechanism is required in order to elucidate an effective therapeutic approach to enhance the sensitivity of lung cancer to EGFR‑TKI. In the present study, EGFR‑TKI erlotinib‑sensitive H358, H322 and H441 lung cancer cells, erlotinib‑moderately sensitive A549 cells, and erlotinib‑insensitive HCC827 cells with EGFR‑mutation (exon 19 deletion) were used to detect the mRNA and protein expression of the EMT‑associated proteins E‑cadherin and vimentin, and napsin A, by reverse transcription‑quantitative polymerase chain reaction analysis and western blotting. It was observed that the E‑cadherin expression level in erlotinib‑sensitive cells was increased compared with the moderately sensitive A549 cells and HCC827 cells; however, vimentin exhibited opposite expression, suggesting a correlation between EMT and erlotinib sensitivity in lung cancer cells. The napsin A expression level was observed to be positively associated with erlotinib sensitivity. In addition, napsin A highly‑expressingH322 cells were used and napsin A‑silenced cells were constructed using small interfering RNA (siRNA) technology, and were induced by transforming growth factor (TGF)‑βl. It was observed that TGF‑βl partially induced the alterations in E‑cadherin and vimentin expression and the occurrence of EMT in napsin A highly‑expressing cells, while TGF‑βl significantly induced EMT via downregulation of E‑cadherin and upregulation of vimentin in napsin A‑silenced cells; cell proliferation and apoptosis assays demonstrated that TGF‑βl induced marked resistance to erlotinib in napsin A‑silenced cells compared with napsin A‑expression cells. These data indicated that napsin A expression may inhibit TGF‑βl‑induced EMT and was negatively associated with EMT‑mediated erlotinib resistance, suggesting that napsin A expression may improve the sensitivity of lung cancer cells to EGFR‑TKI through the inhibition of EMT.

View Figures

View References

1	PDQ Adult Treatment Editorial Board, . Non-small cell lung cancer treatment (PDQ^®): Patient version. NCI. May 12–2002–2015.
2	Soria JC, Mok TS, Cappuzzo F and Jänne PA: EGFR-mutated oncogene addicted non-small cell lung cancer: Current trends and future prospects. Cancer Treat Rev. 38:416–430. 2012. View Article : Google Scholar : PubMed/NCBI
3	Nguyen KS and Neal JW: First-line treatment of EGFR-mutant non-small cell lung cancer: The role of erlotinib and other tyrosine kinase inhibitors. Biologics. 6:337–345. 2012.PubMed/NCBI
4	Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of lung adenocarcinomas to Gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2:e732005. View Article : Google Scholar : PubMed/NCBI
5	Wu PF, Zhu YP, Yang CH, Wang YF and Wang GH: The mechanism and countermeasures on the secondary resistance of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Anti Tumor Pharmacy. 5:42015.
6	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
7	Yang J and Weinberg RA: Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
8	Guarino M, Rubino B and Ballabio G: The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 39:305–318. 2007. View Article : Google Scholar : PubMed/NCBI
9	Robert G, Gaggioli C, Bailet O, Chavey C, Abbe P, Aberdam E, Sabatié E, Cano A, de Herreros Garcia A, Ballotti R and Tartare-Deckert S: SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Res. 66:7516–7523. 2006. View Article : Google Scholar : PubMed/NCBI
10	Voulgari A and Pintzas A: Epithelial-mesenchymal transition in cancer metastasis: Mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta. 1796:75–90. 2009.PubMed/NCBI
11	Neel DS and Bivona TG: Secrets of drug resistance in NSCLC exposed by new molecular definition of EMT. Clin Cancer Res. 19:3–5. 2013. View Article : Google Scholar : PubMed/NCBI
12	Uramoto H, Iwata T, Onitsuka T, Shimokawa H, Hanagiri T and Oyama T: Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res. 30:2513–2517. 2010.PubMed/NCBI
13	Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, Schlederer M, Johns C, Altorki N, Mittal V, et al: TGFb IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci USA. 107:15535–15340. 2010. View Article : Google Scholar : PubMed/NCBI
14	Tatnell PJ, Powell DJ, Hill J, Smith TS, Tew DG and Kay J: Napsins: New human aspartic proteinases. Distinction between two closely related genes. FEBS Lett. 441:43–48. 1998. View Article : Google Scholar : PubMed/NCBI
15	Brasch F, Ochs M, Kahne T, Guttentag S, Schauer-Vukasinovic V, Derrick M, Johnen G, Kapp N, Muller KM, Richter J, et al: Involvement of napsin A in the C- and N-terminal processing of surfactant protein B in type-II pneumocytes of the human lung. J Biol Chem. 278:49006–49014. 2003. View Article : Google Scholar : PubMed/NCBI
16	Ueno T, Linder S, Na CL, Rice WR, Johansson J and Weaver TE: Processing of pulmonary surfactant protein B by napsin and cathepsin H. J Biol Chem. 279:16178–16184. 2004. View Article : Google Scholar : PubMed/NCBI
17	Suzuki A, Shijubo N, Yamada G, Ichimiya S, Satoh M, Abe S and Sato N: Napsin A is useful to distinguish primary lung adenocarcinoma from adenocarcinomas of other organs. Pathol Res Pract. 201:579–586. 2005. View Article : Google Scholar : PubMed/NCBI
18	Chuman Y, Bergman A, Ueno T, Saito S, Sakaguchi K, Alaiya AA, Franzén B, Bergman T, Arnott D, Auer G, et al: Napsin A, a member of the aspartic protease family, is abundantly expressed in normal lung and kidney tissue and is expressed in lung adenocarcinomas. FEBS Lett. 462:129–134. 1999. View Article : Google Scholar : PubMed/NCBI
19	Schauer-Vukasinovic V, Bur D, Kling D, Grüninger F and Giller T: Human napsin A: Expression, immunochemical detection, and tissue localization. FEBS Lett. 462:135–139. 1999. View Article : Google Scholar : PubMed/NCBI
20	Hirano T, Auer G, Maeda M, Hagiwara Y, Okada S, Ohira T, Okuzawa K, Fujioka K, Franzén B, Hibi N, et al: Human tissue distribution of TA02, which is homologous with a new type of aspartic proteinase, napsin A. Jpn J Cancer Res. 91:1015–1021. 2000. View Article : Google Scholar : PubMed/NCBI
21	Hirano T, Gong Y, Yoshida K, Kato Y, Yashima K, Maeda M, Nakagawa A, Fujioka K, Ohira T, Ikeda N, et al: Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma. Lung Cancer. 41:155–162. 2003. View Article : Google Scholar : PubMed/NCBI
22	Ueno T, Linder S and Elmberger G: Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. Br J Cancer. 88:1229–1233. 2003. View Article : Google Scholar : PubMed/NCBI
23	Ueno T, Elmberger G, Weaver TE, Toi M and Linder S: The aspartic protease napsin A suppresses tumor growth independent of its catalytic activity. Lab Invest. 88:256–263. 2008. View Article : Google Scholar : PubMed/NCBI
24	Slack JL, Bi W, Livak KJ, Beaubier N, Yu M, Clark M, Kim SH, Gallagher RE and Willman CL: Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARalpha mRNA using real-time reverse-transcription polymerase chain reaction. J Mol Diagn. 3:141–149. 2001. View Article : Google Scholar : PubMed/NCBI
25	Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N and Haley JD: Epithelial to mesenchymal transition is a determinant of sensitivity of non small cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 65:9455–9462. 2005. View Article : Google Scholar : PubMed/NCBI
26	Grunert S, Jechlinger M and Beug H: Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol. 4:657–665. 2003. View Article : Google Scholar : PubMed/NCBI
27	Zheng JX, Guan SH, Xu Q, Liu JZ and Song P: Inhibition of epithelial-mesenchymal transitionin A549 cell by transfected Napsin A. Chin Med J (Engl). 125:2734–2740. 2012.PubMed/NCBI
28	Nakajima S, Doi R, Toyoda E, Tsuji S, Wada M, Koizumi M, Tulachan SS, Ito D, Kami K, Mori T, et al: N-cadherin expression and epithelial-mesenehymal transition in pancreatic carcinoma. Clin Cancer Res. 10:4125–4133. 2004. View Article : Google Scholar : PubMed/NCBI
29	Ruoslahti E: RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 12:697–715. 1996. View Article : Google Scholar : PubMed/NCBI
30	Juliano RL: Signal transduction by cell adhesion receptors and the cytoskeleton: Functions of integrins, cadherins, selectins, and immunoglobulin-superfamily members. Annu Rev Pharmacol Toxicol. 42:283–323. 2002. View Article : Google Scholar : PubMed/NCBI
31	Hynes RO: Integrins: Bidirectional, allosteric signaling machines. Cell. 110:673–687. 2002. View Article : Google Scholar : PubMed/NCBI
32	Li Y, Yang J, Dai C, Wu C and Liu Y: Role for integrin-linked kinase in mediating tubular epithelial to mesenchymal transition and renal interstitial fibrogenesis. J Clin Invest. 112:503–516. 2003. View Article : Google Scholar : PubMed/NCBI
33	Bhowmick NA, Zent R, Ghiassi M, McDonnell M and Moses HL: Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity. J Biol Chem. 276:46707–46713. 2001. View Article : Google Scholar : PubMed/NCBI
34	Hauck CR, Sieg DJ, Hsia DA, Loftus JC, Gaarde WA, Monia BP and Schlaepfer DD: Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells. Cancer Res. 61:7079–7090. 2001.PubMed/NCBI
35	Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH and Schlaepfer DD: FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol. 2:249–256. 2000. View Article : Google Scholar : PubMed/NCBI
36	Sieg DJ, Hauck CR and Schlaepfer DD: Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration. J Cell Sci. 112:2677–2691. 1999.PubMed/NCBI
37	Hauck CR, Hsia DA and Schlaepfer DD: The focal adhesion kinase a regulator of cell migration and invasion. IUBMB Life. 53:115–119. 2002. View Article : Google Scholar : PubMed/NCBI
38	Xie B, Zhao J, Kitagawa M, Durbin J, Madri JA, Guan JL and Fu XY: Focal adhesion kinase activates Stat1 in integrin-mediated cell migration and adhesion. J Biol Chem. 276:19512–19523. 2001. View Article : Google Scholar : PubMed/NCBI
39	Nam SJ, Kim S, Kim JE, Lim MS, Elenitoba-Johnson KS, Kim CW and Jeon YK: Aberrant expression ofnapsinA in a subset of malignant lymphomas. Histol Histopathol. 31:213–221. 2016.PubMed/NCBI